NovaBridge Biosciences Research and Development Expense
NovaBridge Biosciences (NBP) reported Research and Development Expense of $62.91 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-04-07
- NovaBridge Biosciences research and development expense for the quarter ending 2020-12-31 was 286.23M CNY, a 9.23% increase year-over-year.
- NovaBridge Biosciences research and development expense for the quarter ending 2019-12-31 was 262.04M CNY.
CNY
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | 810.65M CNY 20-F · filed 2024-04-30 | |||
| 2022-12-31 | 904.90M CNY 20-F · filed 2024-04-30 | |||
| 2022-06-30 | 452.62M CNY 6-K · filed 2022-11-10 | |||
| 2021-12-31 | 1.21B CNY 20-F · filed 2024-04-30 | |||
| 2021-06-30 | 592.99M CNY 6-K · filed 2022-11-10 | |||
| 2020-12-31 | 286.23M CNY derived: 20-F 12 month − 6-K 9 month · filed 2023-05-01 | 984.69M CNY 20-F · filed 2023-05-01 | ||
| 2020-09-30 | 698.46M CNY 6-K · filed 2021-02-05 | |||
| 2019-12-31 | 262.04M CNY derived: 20-F 12 month − 6-K 9 month · filed 2022-04-29 | 840.41M CNY 20-F · filed 2022-04-29 | ||
| 2019-09-30 | 578.38M CNY 6-K · filed 2021-02-05 | |||
| 2018-12-31 | 426.03M CNY 20-F · filed 2021-04-28 | |||
| 2017-12-31 | 267.07M CNY 20-F · filed 2020-04-29 | |||
| 2010-12-31 | 43.60M CNY 20-F · filed 2021-04-28 |
USD
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $55.66M derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | $58.83M derived: sum of 2 quarters · filed 2026-04-07 | $62.91M 20-F · filed 2026-04-07 | ||
| 2025-09-30 | $3.18M derived: 6-K 9 month − 6-K 6 month · filed 2025-12-18 | $7.25M 6-K · filed 2025-12-18 | |||
| 2025-06-30 | $4.07M 6-K · filed 2025-10-06 | ||||
| 2024-12-31 | $6.03M derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | $10.51M derived: sum of 2 quarters · filed 2026-04-07 | $21.77M 20-F · filed 2026-04-07 | ||
| 2024-09-30 | $4.47M derived: 6-K 9 month − 6-K 6 month · filed 2025-12-18 | $15.74M 6-K · filed 2025-12-18 | |||
| 2024-06-30 | $11.27M 6-K · filed 2025-10-06 | ||||
| 2023-12-31 | $21.45M 20-F · filed 2026-04-07 | $114.18M 20-F · filed 2024-04-30 | |||
| 2022-12-31 | $22.55M 20-F · filed 2025-04-03 | $131.20M 20-F · filed 2023-05-01 | |||
| 2022-06-30 | $67.57M 6-K · filed 2022-11-10 | ||||
| 2021-12-31 | $190.34M 20-F · filed 2022-04-29 | ||||
| 2020-12-31 | $48.04M derived: 20-F 12 month − 6-K 9 month · filed 2021-04-28 | $150.91M 20-F · filed 2021-04-28 | |||
| 2020-09-30 | $102.87M 6-K · filed 2021-02-05 | ||||
| 2019-12-31 | $120.72M 20-F · filed 2020-04-29 |